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Background: Alzheimer’s disease (AD) is the leading form of dementia worldwide. The Aβ-peptide is believed to be
the major pathogenic compound of the disease. Since several years it is hypothesized that Aβ impacts the Wnt
signaling cascade and therefore activation of this signaling pathway is proposed to rescue the neurotoxic effect of Aβ.
Findings: Expression of the human Aβ42 in the Drosophila nervous system leads to a drastically shortened life span.
We found that the action of Aβ42 specifically in the glutamatergic motoneurons is responsible for the reduced survival.
However, we find that the morphology of the glutamatergic larval neuromuscular junctions, which are widely used as
the model for mammalian central nervous system synapses, is not affected by Aβ42 expression. We furthermore
demonstrate that genetic activation of the Wnt signal transduction pathway in the nervous system is not able to
rescue the shortened life span or a rough eye phenotype in Drosophila.
Conclusions: Our data confirm that the life span is a useful readout of Aβ42 induced neurotoxicity in Drosophila; the
neuromuscular junction seems however not to be an appropriate model to study AD in flies. Additionally, our results
challenge the hypothesis that Wnt signaling might be implicated in Aβ42 toxicity and might serve as a drug target
against AD.
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Alzheimer’s disease (AD) is a major neurodegenerative
malady, affecting today more than 35 million people
worldwide with the tendency to double in the prevalence
every twenty years [1]. The two major hallmarks of AD
are the intracellular neurofibrillary tangles consisting of
the hyperphosphorylated tau protein and the extracellu-
lar plaques mainly containing the aggregated Aβ peptide.
According to the amyloid hypothesis, Aβ peptides in
their various aggregation states are the major pathogenic
compounds in AD.
Already more than a decade ago, first experiments
suggested the interaction of Aβ with the Wnt (Wingless
[Wg] in Drosophila) signaling cascade and its contribu-
tion to Aβ toxicity [2,3]. Wnt signaling is involved in nu-
merous developmental processes and regulates synaptic* Correspondence: vladimir.katanaev@unil.ch
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article, unless otherwise stated.formation and stability in the adult organism [4]. In the
canonical pathway, the ligand Wnt activates the receptor
Frizzled (Fz) and its co-receptor LRP5/6 to induce
reorganization of the β-catenin-destruction complex, a
protein complex consisting of Axin, APC, glycogen syn-
thase kinase 3β (GSK3β, Shaggy [Sgg] in Drosophila) and
casein kinase, through the scaffolding protein Dishevelled
and the trimeric Go protein [4,5]. Thus Wnt signaling
leads to stabilization of β-catenin and its translocation to
the nucleus where it induces transcription of Wnt target
genes. GSK3β also phosphorylates tau and might be the
integration point of Aβ and tau induced toxicity [6].
Lithium is a well-established drug against psychiatric
disorders that inhibits, amongst other targets, GSK3β [7].
Due to its neuroprotective effect, it has been used in
small-scale trials in patients with AD, although with
contradictory results [8]. In transgenic mouse models of
AD, lithium treatment reduced behavioral impairments
and the Aβ load in mouse brains [9]. Likewise, the
destabilization of cytosolic β-catenin and the neurotoxicityioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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potentially implying Wnt signaling in Aβ toxicity [10].
Additionally, incubation with Wnt3a reduces the neuro-
toxic effect of Aβ in cell culture assays – an effect mediated
by Fz1 [11,12]. Furthermore, it has been demonstrated that
the Aβ peptide can bind to the receptor Fz5 [13]. There-
fore, the Wnt cascade was suggested to serve as a potential
drug target against AD [3].
Most investigations on Wnt signaling and Aβ have
mainly been carried out in mice and cell culture where
the inhibition or activation of the signal pathway can be
achieved pharmacologically. The genetic model organ-
ism Drosophila melanogaster has also been used to study
the mechanisms of AD [14]. In this model, several possi-
bilities to mimic AD are available; amongst others the
neuronal expression of human Aβ42 peptide [15,16].
These flies recapitulate several aspects of AD observed
in patients: they show learning deficits, reduced locomo-
tion, shorter life span and neurodegeneration and amyl-
oid deposition in the brain [15].
However, the link between the Wnt signaling and Aβ has
not been so far investigated using the Drosophila models.
We have recently provided an in-depth characterization of
the Wg-Fz2-Go-Ankyrin2 signaling pathway active on the
presynaptic side of Drosophila neuromuscular junctions
(NMJs) [17]. NMJs are composed of synaptic boutons –
circular structures containing active zones for neurotrans-
mitter release. Being a glutamatergic synapse (unlike most
other synapses in Drosophila), NMJ provides an especially
useful model for mammalian synapses [18]. Expression of
human Aβ42 in Drosophila NMJs has already been per-
formed and reports to induce defective NMJ formation
and functioning [19-21]. Thus we aimed at investigation of
the details of the expected interaction of Aβ42 and the
Wnt signaling pathway in this system.
Pan-neuronal expression of secreted Aβ42 (using the
elav-Gal4 driver) has previously been shown to reduceA B
Figure 1 Expression of Aβ42 in the nervous system dramatically redu
expressed either with the pan-neuronal driver elav-Gal4 (A) or the driver D42-
comparing the controls elav-Gal4 and D42-Gal4 to Aβ42 expression, respective
Co-expression of Fz2 or RNAi-Sgg did not rescue life span. P-values are calculathe life span of Drosophila [15,16]. We recapitulated these
findings (Figure 1A) and further showed that a similar
reduction in the life span can be achieved through Aβ42
expression by a motoneuron-specific driver D42-Gal4
(Figure 1B). Indeed, Aβ42 caused a reduction of the me-
dian survival from 30 days (elav-Gal4 control, n = 62) to
10 days (elav-Gal4; UAS-Aβ42, n = 74) (p < 0.0001, Log-
rank test) and of the maximal life span from 42 to 16 days
when the pan-neuronal driver was used (Figure 1A), and
from 35 days (D42-Gal4 control, n = 60) to 12 days (D42-
Gal4; UAS-Aβ42, n = 59) (p < 0.0001, Log-rank test) and
the maximal life span from 49 to 19 days when the
motoneuron-specific driver was used (Figure 1B). This
effect is dose-dependent: increasing the amount of Gal4
produced per cell by adding another motoneuron-specific
driver OK371-Gal4 to D42-Gal4 to express the Aβ42 pep-
tide further reduced the median life span to 10 days (p =
0.0028, Log-rank test) and the maximal survival to 14 days
(Figure 1B). Cumulatively, these findings suggest that the
major effect of Aβ42 on the life span observed previously
[15,16] by the pan-neuronal Aβ42 expression takes place
in glutamatergic neurons.
We further investigated this effect of Aβ42 by analyzing
the morphology of the NMJs in Drosophila larvae. We
expressed Aβ42 through elav-Gal4, D42-Gal4, and the
combination of D42-Gal4 and OK371-Gal4 to increase the
expression levels in the motoneurons. In contrast to previ-
ously published results where Aβ42 expression induced
small morphological changes in NMJs and expression of
human APP and BACE led to a reduction in bouton num-
ber [20,21], we could not detect an influence of Aβ42 on
the larval synapse. Both in terms of the overall morphology
(Figure 2A) and in bouton number (Figure 2B), NMJs
appear to be unaffected by Aβ42.
We further aimed at investigating the potential inter-
action of Aβ42 and the Wnt signaling cascade. Given the
absence of the expected phenotypes of Aβ42 expressionces the life span. (A-B) Survival curves of the indicated genotypes
Gal4 which expresses in the glutamatergic motoneurons (B). P < 0.0001
ly. p = 0.0028 comparing Aβ42; D42-Gal4 and Aβ42/OK371-Gal4; D42-Gal4.
ted with the Log-rank test.
A B
Figure 2 The morphology and bouton number of NMJ are unaffected by neuronal Aβ42 expression. (A) Representative images of NMJs
on muscle 6/7 of elav-Gal4, Aβ42; elav-Gal4, and Aβ42; D42-Gal4 stained with Dlg to visualize the postsynaptic side and HRP to visualize the
neuron. Aβ42 expression does not change NMJ morphology. (B) quantification of the bouton number as mean ± sem in percent of control.
n.s. means ‘not significant’ compared to control as calculated with student’s t-test.
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could not use this readout to study the potential inter-
action between Aβ42 and the pathway. We thus decided
to use the life span reduction as the readout. To this end,
we co-expressed Aβ42 together with Fz2 – the main Wnt
receptor in the Drosophila nervous system [17] – or to-
gether with the RNAi construct targeting Sgg to activate
Wg signaling [17]. We used both the elav-Gal4 and D42-
Gal4 drivers. We also tried co-expression of Aβ42 with
the constitutively active form of Gαo (Gαo [Q205L]) – the
Fz2 transducer in the NMJs [17], but this was lethal with
either driver, probably due to involvement of the trimeric
Go protein in other neuronal activities.
In the motoneurons, co-expression of Fz2 or RNAi-
Sgg together with Aβ42 slightly increased the survivalA B C
Figure 3 The rough eye phenotype induced by Aβ42 is not rescued b
driver) ommatidia are arranged in a regular array. The other parental line, G
Aβ42 in the eyes with the driver GMR-Gal4 results in a rough eye phenotyp
Gαo [Q205L] (D).compared to Aβ42 expression alone (Figure 1B). How-
ever, this was due to a titration effect since an unrelated
protein (myr-mRFP) was also able to similarly rescue
the life span. In pan-neuronal expression, neither Fz2
nor RNAi-Sgg could significantly increase the median
survival, although the maximum life span was increased
upon co-expression of Fz2 (Figure 1A). Cumulatively,
these results indicate that overactivation of the Wnt
signaling transduction pathways in neurons using the
genetic tools available in Drosophila does not rescue the
toxicity (manifested by a shortened life span) induced by
secreted Aβ42.
This conclusion is further corroborated using another
Drosophila readout – insect’s eye. Aβ42 expression in
the eyes using the GMR-Gal4 driver leads to a rough eyeD
y RNAi-Sgg or Gαo [Q205L]. (A) In the control eye (Aβ42 without
MR-Gal4, also shows similar wild-type arrangement. (B) Expression of
e. This is not rescued by co-expression of neither RNAi-Sgg (C) nor
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Gαo [Q205L] with Aβ42 and could not observe a rescue of
the eye roughness (Figure 3). This confirms in a different
setting that genetic activation of the Wnt signaling cascade
does not rescue Aβ42 induced toxicity in Drosophila.
However, it has been previously reported that expres-
sion of the dominant-negative form of Sgg, SggS9E, res-
cues the shortened life span of Drosophila that express
the arctic Aβ42 peptide [22]. The arctic peptide was
shown to decrease Ser9 phosphorylation of Sgg and
thereby upregulate its activity [22]. In contrast another
study shows no change in phosphorylation of Sgg when
wild-type Aβ42 is expressed [20]. The arctic variant ac-
cumulates intracellularly in mice [23,24]; therefore it is
likely that the arctic variant of Aβ42 exerts a different
pathogenic mechanism than the wild-type peptide. Our
data suggest that secreted wild-type Aβ42 acts primarily
on glutamatergic neurons in Drosophila, but induces the
toxicity independently from Wnt signaling.
Taken together, our results demonstrate that Aβ42 ex-
pression in glutamatergic neurons is responsible for the
dramatic shortened life span manifested in Drosophila
models of AD. However, the glutamatergic NMJs seem not
to be appropriate to study the Aβ42-induced changes on a
single cell level. In addition, our genetic interaction analysis
challenges the widely accepted idea that Aβ42 inhibits Wnt
signaling and that Wnt pathway overactivation might re-
duce the Aβ42 toxicity. This concept is based on numerous
studies, mainly relying on the usage of LiCl and its effects
on the AD phenotypes. We suggest that caution is taken
when interpreting these data, as LiCl is not a specific inhibi-
tor of GSK3β/Sgg, and further since this kinase has many
other functions outside the Wnt signaling pathway [7].
Methods
Life span, eye analysis and Drosophila stocks
For the life span test, flies were crossed at 25°C and 5 male
and 5 female newly hatched flies were pooled and trans-
ferred to 28.5°C. Flies were transferred to fresh food every
other day and time-to-death was recorded for individual
flies. 59 to 90 flies were analyzed for each genotype. Ana-
lysis of survival was performed with GraphPad Prism 5,
p-values were calculated with the Log-rank test.
Eye phenotypes were analyzed after crossing to GMR-
Gal4 at 25°C.
The following stock were used: elav-Gal4, D42-Gal4,
GMR-Gal4 (all from Bloomington stock center), UAS-
RNAi-Sgg (VCRC #7005), UAS-Aβ42 [16]. The lines
OK371-Gal4, UAS-Fz2, and UAS-Gαo [Q205L] were
used as described [17].
Immunohistochemistry
For the analysis of the neuromuscular junctions, crosses
were set up at 28.5°C and wandering third instar larvaewere dissected and stained as previously described [17].
Primary antibodies were: Cy3-coupled goat anti-HRP
(123-165-021, Jackson ImmunoResearch) at 1:200 and
mouse anti-Dlg (4 F3, Developmental Studies Hybrid-
oma Bank) at 1:100. Boutons were identified based on
presynaptic HRP and postsynaptic Dlg staining. Statis-
tical analysis was performed with GraphPad Prism 5.
Data are present as mean ± sem.
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